ClinicalTrials.gg
Not yet recruitingNCT07323225RCTUpdated Jan 7, 2026

Neural Mobilization and Capsular Stretching in Adhesive Capsulitis

An interventional study of capsular stretching plus neural mobilization and anterior, inferior and posterior capsular stretching in Adhesive Capsulitis, sponsored by Prince Sattam Bin Abdulaziz University. Not yet recruiting at 1 site in Saudi Arabia. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Prince Sattam Bin Abdulaziz University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Restriction of glenohumeral (GH) mobility in patients with adhesive capsulitis (AC) was known owing to capsular adhesion. There is a little evidence about the involvement of neural restriction in limiting range of motion (ROM) of the GH joint in patients with AC. Objectives: The purpose of this study is to investigate the combined effect of median nerve mobilization and capsular stretching on improving shoulder external rotation, abduction and internal rotation ROM among patients with AC. Methods Thirty patients will be randomly assigned into two equal groups : Group (A) will receive median nerve mobilization and capsular stretching while Group (B) will receive only capsular stretching (anterior, posterior and anteroinferior capsular stretching). Both groups will receive passive and self-assisted exercises. All patients in both groups will be evaluated pre and post treatment for GH external rotation, abduction and internal rotation ROM.

02

Conditions studied

  • Adhesive Capsulitis

Browse trials for

Keywords

  • Adhesive capsulitis
  • neural mobilization
  • capsular stretch
03

In context

Bursitis

383 studies on the registry are indexed under Bursitis; 111 are open to participants now.

This study's planned enrollment of 50 is above the median of 44 across 346 interventional studies indexed under Bursitis.

Browse Bursitis studies →

Lead sponsor

Prince Sattam Bin Abdulaziz University is the lead sponsor of 35 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients from both gender (male \&female) will be included if they would have second or third stage AC with their age between forty and seventy years
  • experiencing pain, capsular adhesions, and a reduction of greater than fifty percentage in passive ROM of the GH joint (external rotation, abduction, and internal rotation compared to the sound side
  • lasting for a minimum of three months. Patients with positive upper limb tension test-1 will be also included in this study

Exclusion criteria

Exclusion Criteria:

  • they would have stroke,Parkinson's diseases that interfere with shoulder muscles activity
  • diabetes
  • traumatic shoulder conditions
  • glenohumeral osteoarthritis confirmed by x-ray
  • previous surgery, and manipulation of the affected GH joint under general anesthesia
  • Patients with passive elbow extension ROM
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Neural mobilization group

    neural mobilization plus capsular stretching

    Other: capsular stretching plus neural mobilization

  • Active comparator
    Capsular stretching group

    capsular stretching

    Other: anterior, inferior and posterior capsular stretching

  • Active comparator
    Control group

    traditional execises

    Other: traditional exercises

Interventions

  • Othercapsular stretching plus neural mobilization

    anterior, posterior and inferior capsular stretching and neural mobilization

  • Otheranterior, inferior and posterior capsular stretching

    anterior, inferior and posterior glenohumeral capsular stretching

  • Othertraditional exercises

    stretching exercises for anterior GH musculture plus auto passive exercises and pendulum exercises

06

What researchers measure

Primary outcomes

  1. pain intensity

    pain was assessed by VAS which has two ends. the left end indicates no pain where the right end indicates maximal pain

    Time frame: 4 Weeks

  2. central sensitization

    central sensitization will be assessed by the the arabic version of central sensitizatuion questionnaire. To understand CSI scores, the following severity categories have been established: subclinical = 0 to 29; mild = 30 to 39; moderate = 40 to 49; severe = 50 to 59; and extreme = 60 to 100

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Coppieters MW, Butler DS. Do 'sliders' slide and 'tensioners' tension? An analysis of neurodynamic techniques and considerations regarding their application. Man Ther. 2008 Jun;13(3):213-21. doi: 10.1016/j.math.2006.12.008. Epub 2007 Mar 30. PubMed 17398140 ↗
  • Martinez-Merinero P, Lluch E, Gallezo-Izquierdo T, Pecos-Martin D, Plaza-Manzano G, Nunez-Nagy S, Falla D. The influence of a depressed scapular alignment on upper limb neural tissue mechanosensitivity and local pressure pain sensitivity. Musculoskelet Sci Pract. 2017 Jun;29:60-65. doi: 10.1016/j.msksp.2017.03.001. Epub 2017 Mar 10. PubMed 28319883 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Apr 2026, 3 months later.

Of 217 non-industry interventional studies with no phase under Bursitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 3 months is below that.

Counting every sponsor, half of 217 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 7, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 10, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323225
Lead sponsor
Prince Sattam Bin Abdulaziz University
Responsible party
Mohammad Moustafa Aldosoukki Hegazy (assisstant professor , department of health and rehabilitation sciences, college of applied medical siences, Prince Sattam Bin Abdulaziz University) — Principal investigator
First posted
Jan 7, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 10, 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Mohammed Hegazy
Contact
mohamed.mostafa@pt.cu.edu.eg
00966566169893 ext. 00966115886387

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion